9:01 PM
 | 
Nov 08, 2017
 |  BC Extra  |  Company News

IM Therapeutics emerges from stealth with small molecule for T1D

ImmunoMolecular Therapeutics LLC (Broomfield, Colo.) emerged from stealth mode with a small molecule candidate that aims to treat Type I diabetes by preventing the initiation of the autoimmune response against insulin-producing beta cells.

The company was founded in 2015 based on research at the University of Colorado that suggested human leukocyte antigen (HLA) molecules can "mis-present" autoantigens to...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >